HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Halozyme Therapeutics (HALO) Tops Q3 EPS by 5c; Offers FY23 Guidance
November 6, 2023 4:05 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.75, $0.05 better than the analyst estimate of $0.70. Revenue for the quarter came in at $216 million versus the consensus estimate of $218.7 million.
GUIDANCE:
Halozyme Therapeutics sees FY2023 EPS of $2.70-$2.80, versus the consensus of $2.65.... More
